m+Medelevator.RU
← Поиск публикаций
Global heart · 2025

Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Rosende Andres, Romero Cesar, DiPette Donald J, Brettler Jeffrey, Van der Stuyft Patrick, Satheesh Gautam, Perel Pablo, Chapman Niamh, Moran Andrew E, Schutte Aletta E, Sharman James E, Irazola Vilma, Huffman Mark D, Campbell Norm R C, Salam Abdul, Lanas Fernando, Coca Antonio, Garcia-Zamora Sebastian, Ferreiro Alejandro, Lopez-Jaramillo Patricio, Rico-Fontalvo Jorge, Ridley Emily, Picone Dean, Flood David, Piñeiro Daniel José, Ojeda Carolina Neira, Rodriguez Gonzalo, Wellmann Irmgardt A, Orias Marcelo, Rivera Marcela, Reyes Matías Villatoro, Onuma Oyere, Ramroop Shaun, Khan Taskeen, Gonzalez Yamile Valdes, Barroso Weimar Kunz Sebba, Plavnik Frida L, Zuniga Eric, Grassani Ana María, Tajer Carlos, Zaidel Ezequiel, Marin Marcos J, Cyr-Philbert Shana, Amorin Ignacio, Diaz Aguilera Miguel Angel, Bortolotto Luiz, Avezum Alvaro, Ribeiro Antonio Luiz P, Tobe Sheldon, Aumala Teresa, Angell Sonia, Lavados Pablo, Martins Sheila Ouriques, Echeverri Ana Munera, Jaffe Marc G, Prabhakaran Dorairaj, Parati Gianfranco, Zhang Xin Hua, Rodgers Anthony, Yusuf Salim, Whelton Paul K, Ordunez Pedro

Аннотация

BACKGROUND: HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative, aimed at helping countries enhance hypertension and cardiovascular disease (CVD) risk management in primary care settings. Its core implementation tool, the HEARTS Clinical Pathway, has been adopted by 28 countries. To improve the care of hypertension, diabetes, and chronic kidney disease (CKD), HEARTS 2.0 was developed as a three-phase process to integrate evidence-based interventions into a unified care pathway, ensuring consistency across fragmented guidelines. This paper focuses on Phase 1, highlighting targeted interventions to improve and update the HEARTS Clinical Pathway.

METHODS: First, the coordinating group defined the project's scope, objectives, principles, methodological framework, and tools. Second, international experts from different disciplines proposed interventions to enhance the HEARTS Clinical Pathway. Third, the coordinating group harmonized these proposals into unique interventions. Fourth, experts appraised the appropriateness of the proposed interventions on a 1-to-9 scale using the adapted RAND/UCLA Appropriateness Method. Finally, interventions with a median score above 6 were deemed appropriate and selected as candidates to enhance the HEARTS Clinical Pathway.

RESULTS: Building on the existing HEARTS Clinical Pathway, 45 unique interventions were selected, including community-based screening, early detection and management of risk factors, lower blood pressure thresholds for diagnosing hypertension in high-CVD-risk patients, reinforcement of single-pill combination therapy, inclusion of sodium-glucose cotransporter-2 inhibitors for patients with diabetes, CKD, or heart failure, expanded roles for non-physician health workers in team-based care, and strengthened clinical documentation, monitoring, and evaluation.

CONCLUSION: HEARTS 2.0 Phase 1 identifies key interventions to integrate and improve hypertension and cardiovascular-kidney-metabolic care within primary care, enabling their seamless incorporation into a unified and effective clinical pathway. This process will inform an update to the HEARTS Clinical Pathway, optimizing resources, reducing care fragmentation, improving care delivery, and advancing health equity, thereby supporting global efforts to combat the leading causes of death and disability.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты